These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21226658)

  • 1. Developing the Sentinel System--a national resource for evidence development.
    Behrman RE; Benner JS; Brown JS; McClellan M; Woodcock J; Platt R
    N Engl J Med; 2011 Feb; 364(6):498-9. PubMed ID: 21226658
    [No Abstract]   [Full Text] [Related]  

  • 2. Conducting prospective sequential surveillance in real-world dynamic distributed databases.
    Maro JC; Eworuke E; Hou L; Welch EC; Goulding MR; Izem R; Lee JY; Toh S; Fireman B; Nguyen MD
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1331-1335. PubMed ID: 32449261
    [No Abstract]   [Full Text] [Related]  

  • 3. Investments in infrastructure for diverse research resources and the health of the public.
    Psaty BM; Larson EB
    JAMA; 2013 May; 309(18):1895-6. PubMed ID: 23652519
    [No Abstract]   [Full Text] [Related]  

  • 4. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

  • 5. The new Sentinel Network--improving the evidence of medical-product safety.
    Platt R; Wilson M; Chan KA; Benner JS; Marchibroda J; McClellan M
    N Engl J Med; 2009 Aug; 361(7):645-7. PubMed ID: 19635947
    [No Abstract]   [Full Text] [Related]  

  • 6. Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration's Sentinel system.
    Brown JS; Maro JC; Nguyen M; Ball R
    J Am Med Inform Assoc; 2020 May; 27(5):793-797. PubMed ID: 32279080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System.
    Cocoros NM; Fuller CC; Adimadhyam S; Ball R; Brown JS; Dal Pan GJ; Kluberg SA; Lo Re V; Maro JC; Nguyen M; Orr R; Paraoan D; Perlin J; Poland RE; Driscoll MR; Sands K; Toh S; Yih WK; Platt R;
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):827-837. PubMed ID: 33797815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
    Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of unique device identification in the digital health infrastructure.
    Wilson NA; Drozda J
    JAMA; 2013 May; 309(20):2107-8. PubMed ID: 23695480
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 11. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 12. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
    Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
    [No Abstract]   [Full Text] [Related]  

  • 13. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1997 Jul; 278(1):15. PubMed ID: 9207323
    [No Abstract]   [Full Text] [Related]  

  • 15. Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care.
    Adimadhyam S; Barreto EF; Cocoros NM; Toh S; Brown JS; Maro JC; Corrigan-Curay J; Dal Pan GJ; Ball R; Martin D; Nguyen M; Platt R; Li X
    J Am Soc Nephrol; 2020 Nov; 31(11):2506-2516. PubMed ID: 33077615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four health data networks illustrate the potential for a shared national multipurpose big-data network.
    Curtis LH; Brown J; Platt R
    Health Aff (Millwood); 2014 Jul; 33(7):1178-86. PubMed ID: 25006144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common Models, Different Approaches.
    Gagne JJ
    Drug Saf; 2015 Aug; 38(8):683-6. PubMed ID: 26088718
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-World Evidence of Treatment Effects: The Useful and the Misleading.
    Schneeweiss S
    Clin Pharmacol Ther; 2019 Jul; 106(1):43-44. PubMed ID: 30942896
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in the Use of Real-World Evidence for Medical Devices: An Update From the National Evaluation System for Health Technology.
    Fleurence RL; Shuren J
    Clin Pharmacol Ther; 2019 Jul; 106(1):30-33. PubMed ID: 30888048
    [No Abstract]   [Full Text] [Related]  

  • 20. Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk.
    Quinney SK
    Clin Pharmacol Ther; 2019 Jul; 106(1):72-74. PubMed ID: 31184772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.